MINERALYS THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 2nd, 2023 Company Industry Jurisdiction
INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification Agreement • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 18th, 2023 Company Industry JurisdictionThis Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Mineralys Therapeutics, Inc. a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement of expenses.
MINERALYS THERAPEUTICS, INC. Common Stock ($0.0001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENTAtm Equity Offering Sales Agreement • March 21st, 2024 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 21st, 2024 Company Industry Jurisdiction
MINERALYS THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 8th, 2024 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 8th, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (the “Agreement”) is made as of February 7, 2024 (the “Effective Date”), by and between Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers whose names and addresses are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 2nd, 2023 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 1, 2022, as amended, by and among Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on Schedule A hereto (each, an “Investor”).
ContractEmployment Agreement • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledJanuary 18th, 2023 Company Industry Jurisdiction[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential.
Re: Amended and Restated Employment LetterEmployment Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledFebruary 2nd, 2023 Company Industry JurisdictionThis amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated March 8, 2022, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the date on which the registration statement on Form S-1 filed in connection with the Company’s initial public offering (“IPO”) becomes effective. In consideration of the mutual promises herein contained, the parties agree as follows:
ContractEmployment Offer Letter • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledJanuary 18th, 2023 Company Industry Jurisdiction[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENTLicense Agreement • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 18th, 2023 Company Industry JurisdictionThis License Agreement (the “Agreement”) made and executed as of [***], by and between Mitsubishi Tanabe Pharma Corporation, a corporation organized under the laws of Japan and having its principal place of business at 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka 541-8505, Japan (“MTPC”), and Mineralys Therapeutics, Inc., a corporation organized under the laws of the state of Delaware and having its principal of business at 100 Pine Street, Suite 1250, San Francisco, CA 94111, U.S.A. (“MINERALYS”). MTPC and MINERALYS are sometimes referred to individually as a “Party” and collectively as “Parties”.
ContractEmployment Offer Letter • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledJanuary 18th, 2023 Company Industry Jurisdiction[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential.
Re: Amended and Restated Employment LetterEmployment Letter • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledFebruary 2nd, 2023 Company Industry JurisdictionThis amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated October 9, 2020, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the date on which the registration statement on Form S-1 filed in connection with the Company’s initial public offering (“IPO”) becomes effective. In consideration of the mutual promises herein contained, the parties agree as follows: